Author

P. Razavi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

S. Chandarlapaty· 4 shared A. Safonov· 2 shared B. Weigelt· 2 shared J. S. Reis-Filho· 2 shared A. Boire· 1 shared A. Cercek· 1 shared A. Fushimi· 1 shared A. Gris-Oliver· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

S. Chandarlapaty

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Multimodal histopathologic models stratify hormone receptor-positive early breast cancer

K. M. Boehm, O. S. M. El Nahhas, A. Marra, P. Selenica, H. Y. Wen, B. Weigelt, E. D. Paul, P. Cekan, R. Erber, C. M. L. Loeffler, E. Guerini-Rocco, N. Fusco, C. Frascarelli, E. Mane, E. Munzone, , J. N. Kather

This paper develops a multimodal transformer model using H&E images and text reports to predict recurrence scores in hormone receptor-positive breast cancer, achieving high accuracy and generalizability.

bioRxiv · Feb 23, 2024Pathology

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion

R. Kudo, A. Safonov, E. M. da Silva, Q. Li, H. Shao, M. Will, A. Fushimi, H. Nakshatri, J. S. Reis-Filho, S. Goel, A. Koff, B. Weigelt, Q. J. Khan, P. Razavi, S. Chandarlapaty

The paper identifies TP53 loss and MDM2 amplification as factors associated with poor long-term response to CDK4/6 inhibition in breast cancer and shows that CDK2 inhibition can overcome this resistance.

bioRxiv · Aug 25, 2023Cancer Biology

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

B. Nguyen, C. Fong, A. Luthra, S. A. Smith, R. G. DiNatale, S. Nandakumar, H. Walch, W. K. Chatila, R. Madupuri, R. Kundra, C. M. Bielski, B. Mastrogiacomo, A. Boire, S. Chandarlapaty, K. Ganesh, , Varghes

The paper analyzes genomic data from 25,000 patients to identify associations between genomic alterations and metastatic patterns across 50 tumor types, finding chromosomal instability correlates with metastatic burden in some cancers.

bioRxiv · Jun 28, 2021Cancer Biology

Personalized Cancer Therapy Prioritization Based on Driver Alteration Co-occurrence Patterns

L. Mateo, M. Duran-Frigola, A. Gris-Oliver, M. Palafox, M. Scaltriti, P. Razavi, S. Chandarlapaty, J. Arribas, M. Bellet, V. Serra, P. Aloy

The paper identifies actionable genomic vulnerabilities in cancer by analyzing driver alteration co-occurrence patterns and validates predictions in mice, improving drug response modeling from patient data.

bioRxiv · Sep 18, 2020Cancer Biology